In August 2026, global capital markets are witnessing a subtle shift in investor focus. Over the past two years, AI-driven tech stocks have surged, pushing the Nasdaq to historic highs, but concerns about overvaluation and crowded trades have grown. In the search for the next growth engine, a sector once forgotten and now quietly rising has returned to the spotlight—the US biotech and pharmaceutical sector.
For investors pondering "Why buy US stocks?", the biotech sector offers a compelling answer. It is not only a cornerstone of the long-term US bull market but has also demonstrated unique resilience and explosive power in 2026. This article analyzes why now is a strategic window to invest in US biotech stocks from four dimensions: industry cycles, technological innovation, macro hedging, and asset allocation.
Resilience Across Cycles: From the "Lost Decade" to Value Return
Looking back at the past decade, the US pharmaceutical sector experienced a long period of dormancy. Constrained by the patent cliff, tightening regulations, and geopolitical impacts, growth stalled for many traditional pharma giants, with biotech indices underperforming the broader market for a long time. However, entering 2026, a fundamental reversal has occurred.
This reversal stems first from a fundamental improvement in fundamentals. Large pharma companies have successfully filled revenue gaps left by expiring patents through years of internal R&D integration and external M&A. More importantly, with global aging intensifying—especially as the US "Baby Boomer" generation fully retires—demand for healthcare services is showing rigid and explosive growth. Driven by demographics rather than economic cycles, this gives the sector strong defensive attributes during economic fluctuations.
From a valuation perspective, after long adjustments, the P/E ratio of the US pharma sector relative to tech stocks is at a historically high discount. Within the S&P 500, the healthcare sector's contribution to earnings has steadily risen, yet its valuation remains far below Communication Services and IT. The potential for a "Davis Double Play"—simultaneous earnings growth and valuation restoration—is the key logic attracting smart money.
The Innovation Wave Post-GLP-1: From Weight Loss Drugs to Comprehensive Health Management
If 2023-2024 marked the first year GLP-1 drugs (like semaglutide and tirzepatide) ignited the weight loss market, then 2026 is the year this track enters the "deep water" and "broad application" phase. Market focus is no longer just on weight loss, but on the broad application of these drugs in cardiovascular protection, kidney disease treatment, and even metabolic disorders.
Industry analysis shows that in the first half of 2026, clinical data on GLP-1 drugs reducing the risk of major adverse cardiovascular events was further validated. This directly pushed inclusion in more insurance reimbursement lists, greatly releasing market space. Investors are realizing this is not just a multi-billion dollar weight loss market, but a trillion-dollar chronic disease management ecosystem. This cognitive upgrade directly supports the sustained stock strength of giants like Eli Lilly and Novo Nordisk, driving prosperity across the entire supply chain.
However, the appeal of US pharma is not limited to GLP-1. In fields like oncology immunotherapy, gene editing (CRISPR), antibody-drug conjugates (ADCs), and Alzheimer's treatment, the US maintains an absolute global lead. In 2026, multiple gene therapies for refractory cancers received FDA accelerated approval, marking a key step from "symptomatic treatment" to "one-time cures." These disruptive innovations are the source of long-term value for the sector and a core reason global capital cannot abandon the US market.
M&A Boom: Big Pharma's "Anxiety" and Biotech's "Spring"
Beyond internal growth, another significant feature of the 2026 US pharma market is the explosion in M&A activity. Facing the high risks and long cycles of R&D, Big Pharma chooses to "buy" to replenish pipelines. This directly catalyzed a valuation recovery for biotech companies.
As the Fed maintained relatively neutral interest rates in 2026, the financing environment improved compared to the previous two years, though secondary market divergence remains severe. Small biotechs with core data and good cash flow have become prey for Big Pharma. Statistics show total biotech M&A deals announced in the first half of 2026 hit a record high. This trend offers investors two clear paths to profit: buy industry giants with strong cash flow and M&A capability, or lie in wait for undervalued potential acquisition targets with breakthrough pipelines.
Macro Hedging Tool: Dual Attributes of Inflation Resistance and Safe Haven
When discussing "Why buy US stocks," the macro environment is unavoidable. In the second half of 2026, although global inflationary pressures eased, they have not fully returned to the Fed's 2% target. In environments of high inflation or interest rate volatility, the pharma sector often demonstrates excellent inflation resistance.
First, healthcare service prices usually have strong stickiness, rising with inflation to protect corporate margins. Second, the pharma industry typically possesses abundant free cash flow, enabling it to raise dividends or buy back shares during rate hike cycles, providing stable returns to shareholders. For investors seeking long-term stable income, while the dividend yield of US pharma stocks may not match utilities, their accompanying capital appreciation potential is unmatched by the latter.
Furthermore, amidst increasingly complex geopolitical risks, the US pharma sector, as a "domestic demand" asset, is relatively less affected by global supply chain breaks and trade frictions. Whether in raw material supply or final sales markets, the US possesses strong self-sufficiency. This independence makes the pharma sector a rare safe haven in global asset allocation.
Investment Strategy: How to Capture the Golden Age of US Pharma
For domestic investors, strategizing is key when allocating to US pharma. Given the uncertainty of individual stock R&D, using ETFs (Exchange Traded Funds) for sector allocation may be a safer choice for ordinary investors. For example, ETFs tracking the S&P 500 Healthcare Index or Nasdaq Biotechnology Index can diversify the "black swan" risk of a single drug's failure while sharing in the sector's overall growth dividends.
For investors with higher risk appetite and professional research capabilities, consider the following sub-sectors:
- Weight Loss and Metabolic Syndrome Supply Chain: Besides pharma giants, upstream CDMOs (Contract Development and Manufacturing Organizations) and injection device suppliers are worth watching.
- Gene and Cell Therapy: Focus on leading companies with mature technology platforms and commercialized products.
- MedTech and Devices: Surgical robots combined with AI and remote monitoring devices are reshaping the healthcare ecosystem.
Of course, risks remain. Adjustments in US healthcare policy, calls for drug pricing reform, and policy uncertainty from the 2026 US election could cause short-term volatility. However, in the long run, humanity's eternal pursuit of health and the spiral of technological progress determine that the fundamentals of the US pharma sector remain rock-solid.
Conclusion: The Victory of Long-termism
Returning to the origin of "Why buy US stocks," the answer may no longer be limited to those dazzling tech giants. The depth and breadth of the US market empower investors to find quality assets across different economic cycles. The biotech sector, as the crystallization of human wisdom and the guardian of life and health, stands at the starting point of a new innovation cycle.
This anomaly in August 2026 may be not just a short-term rebound, but the prologue to a structural bull market lasting several years. For investors adhering to long-termism and seeking assets that transcend cycles, ignoring the US pharma sector means missing the most certain piece of the puzzle in global capital markets. While AI reconstructs the world, do not forget the innovative forces reconstructing our lifespan. This, perhaps, is one of the most underlying logics for buying US stocks.
